ObsEva successfully issues USD 73.1 million worth of shares in an underwritten public offering

Lenz & Staehelin advised ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, in connection with an underwritten public offering and sale of 4'750'000 shares at a price of USD 15.39 per share pursuant to an underwriting agreement with J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC as representatives of several underwriters.

ObsEva is headquartered in Plan-les-Ouates in the Swiss canton of Geneva. Its shares are listed on the NASDAQ Global Select Market in the United States. The transaction was completed on 22 June 2018. The net proceeds to the company from the offering were approximately USD 67.7 million. The Lenz & Staehelin team was led by Jacques Iffland, partner in the firm's corporate and capital markets practice groups, and included associates Federico Trabaldo Togna, Ariel Ben Hattar and Ann-Sophie Schubert.

On 1 June 2018, ObsEva announced its intention to request the listing of its shares on SIX Swiss Exchange under SIX's international reporting standard. Lenz & Staehelin is acting as listing agent in this context.